What the FDA labels say about taking them together
Daratumumab and iberdomide
Iberdomide's FDA label of August 13, 2026 names daratumumab in its boxed warning section; the daratumumab label PlainMeds reads does not name iberdomide. The iberdomide label: “… infarction, and stroke in patients with multiple myeloma receiving ZENBEXUS with daratumumab and hyaluronidase-fihj and dexamethasone.”
Check it at the source: the daratumumab FDA label on DailyMed (effective September 8, 2026, Janssen Biotech, Inc.); the iberdomide FDA label on DailyMed (effective August 13, 2026, E.R. Squibb & Sons, L.L.C.).
What does the daratumumab label say about iberdomide?
Daratumumab's label (effective September 8, 2026) does not name iberdomide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Darzalex IV), Janssen Biotech, Inc., effective September 8, 2026 (SPL set a4d0efe9-5e54-467e-9eb4-56fa7d53b60b), via openFDA; the full label on DailyMed
What does the iberdomide label say about daratumumab?
Iberdomide label, boxed warningSERIOUS VENOUS AND ARTERIAL THROMBOEMBOLISM Increased risk of deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke in patients with multiple myeloma receiving ZENBEXUS with daratumumab and hyaluronidase-fihj and dexamethasone.
Iberdomide label, warnings and precautionsIn the EXCALIBER-RRMM study evaluating ZENBEXUS in combination with daratumumab and hyaluronidase-fihj and dexamethasone (IberDd), venous thromboembolic events occurred in 6.4% of patients despite mandatory thromboembolism prophylaxis in the IberDd arm (N=204).
Source: FDA drug label (ZENBEXUS), E.R. Squibb & Sons, L.L.C., effective August 13, 2026 (SPL set 3663d9cb-3f66-48ae-bf0a-6958bc0888de), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Daratumumab | Iberdomide | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once